Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma

Drug Delivery and Translational Research

Volumn 1, Issue 2, 2011, Pages 161-174

  Bhagav, Prakash ^a   Trivedi, Vaibhav ^a   Shah, Darshan ^a   Chandran, Sajeev ^a,b  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b LUPIN LIMITED   (India)

Author keywords

Brimonidine tartrate; Eudragit; Glaucoma; Intraocular pressure; Ocular inserts; Polyethylene oxide

Indexed keywords

AMPHOLYTE; BRIMONIDINE; CIPROFLOXACIN; DEXACIP; DEXAMETHASONE; DICLOFENAC; EUDRAGIT; EUDRAGIT RS; EYE DROPS; IOBRIM; MACROGOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRUSHING STRENGTH; DIFFUSION; DRUG DELIVERY SYSTEM; EYE INFLAMMATION; HARDNESS; HYDROPHILICITY; MUCOADHESION; NONHUMAN; OCULAR INSERT; OPEN ANGLE GLAUCOMA; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RABBIT; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TABLET FRIABILITY; TONOMETER;

EID: 84860681553     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-011-0018-2     Document Type: Article

References (24)

1. American Academy of Ophthalmology: Preferred Practice Patterns TM: Open-angle Glaucoma. 2000; 38.
2. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996; 41: S9-18.
3. Burke J, Manlapaz C, Kharlamb A, Runde E, Padillo E, Spada C. In: Lanier, Limbird, editors. Therapeutic use of Alpha-2-adrenoceptor agonists in glaucoma. In alpha-2-adrenergic receptors: structure, function and therapeutic implications. UK: Harwood Academic Publishers; 1996. p. 179-87.
4. Torris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999; 128: 8-14.
5. Cantor BL, Burke J. Drug evaluation: brimonidine. Expert Opin Investig Drugs. 1997; 6: 1063-83.
6. Konstas AGP, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT. Brimonidine 0. 2% given two or three times daily versus timolol maleate 0. 5% in primary angle glaucoma. Am J Ophthalmol. 2001; 131: 729-33.
7. Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 2003; 48: S47-51.
8. El-Shanawany. Ocular delivery of pilocarpine from ocular inserts, S. T. P. Pharm Sci. 1992; 2: 337-41.
9. Weyenberg W, Bozdag S, Foreman P, Remon JP, Ludwig SA. Characterization and in vivo evaluation of ocular minitablets prepared with different bioadhesive Carbopol-starch components. Eur J Pharm Biopharm. 2006; 62: 202-9.
10. Di Colo G, Zambito Y. A study of release mechanisms of different ophthalmic drugs from erodible ocular inserts based on poly(ethylene oxide). Eur J Pharm Biopharm. 2002; 54: 193-9.
11. Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv Drug Deliv Rev. 1995; 16: 94-106.
12. Di Colo G, Burgalassi S, Chetoni P, Fiaschi MP, Zambito Y, Saettone MF. Relevance of polymer molecular weight to the in vitro/in vivo performances of ocular inserts based on poly(ethylene oxide). Int J Pharm. 2001; 220: 169-77.
13. Bhagav P, Deshpande P, Pandey S, Chandran S. Development and validation of stability indicating UV spectrophotometric method for the estimation of brimonidine tartrate in pure form, formulations and preformulation studies. Der Pharmacia Lettre. 2010; 2(3): 106-22.
14. Chong HS, Park H, Kelly P, Robinson JR. Bioadhesive polymers as platforms for oral controlled drug delivery II: synthesis and evaluation of some swelling, water-insoluble bioadhesive polymers. J Pharm Sci. 1985; 74: 399-405.
15. Yong CS, Choi JS, Quan QZ, Rhee JD, Kim CK, Lim SJ, et al. Effect of sodium chloride on the gelation temperature, gel strength and bioadhesive force of poloxamer gels containing Diclofenac sodium. Int J Pharm. 2001; 226: 195-205.
16. ICH. International Conference on Harmonisation (ICH) of Technical requirements for Registration of Pharmaceuticals for Human Use. Harmonised triplicate guideline on validation of analytical procedures: Methodology, recommended for adoption at step 4 of ICH process on November 1996 by ICH steering committee, published by IFPMA, Switzerland. 1996.
17. Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1994; 82: 377-90.
18. Percicot CL, Schnell CR, Debon C, Hariton C. Continuous intraocular pressure measurement by telemetry in alpha-chymotrypsin-induced glaucoma model in the rabbit: effects of timolol, dorzolamide, and epinephrine. J Pharmacol Toxicol Methods. 1996; 36: 223-8.
19. Anumolu SS, Singh Y, Gao D, Stein S, Sinko JP. Design and evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for sustained pharmacological response. J Control Release. 2009; 137: 152-9.
20. Pongjanyakul T, Puttipipatkhachorn S. Modulating drug release and matrix erosion of alginate matrix capsules by microenvironmental interaction with calcium ion. Eur J Pharm Biopharm. 2007; 67: 187-95.
21. Tatavarti AS, Mehta KA, Augsburger LL, Hoag SW. Influence of methacrylic and acrylic acid polymers on the release performance of weakly basic drugs from sustained release matrices. J Pharm Sci. 2004; 93: 2310-31.
22. Bremmecker KD. Model to determine the adhesive time of mucosal adhesive ointments in vitro. Pharm Ind. 1983; 45: 417-9.
23. Himber J, De Burlet G, Andermann G. Effects of adrenergic agents on alpha-chymotrypsin induced ocular hypertension in albino and pigmented rabbits: a comparative study. J Ocul Phurmacol. 1989; 5: 93-8.
24. Fernandez DR, Ramirez JM, Trivino A, Sanchez D, Paraiso P, Garcia DLM, et al. Experimental glaucoma significantly decreases atria1 natriuretic factor receptors in the ciliary processes of the rabbit eye. Exp Eye Res. 1991; 53: 591-6.